Survival Outcomes
12 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer (NCT05311566) | Lei Li | 2022-03-27 |
| Niraparib Plus Anlotinib for Recurrent Ovarian Cancer (NCT05311579) | Lei Li | 2022-03-27 |
| Donafenib for Recurrent Cervical Cancer (NCT05310331) | Lei Li | 2022-03-27 |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer (NCT05310383) | Lei Li | 2022-03-27 |
| Prognosis of Low-grade Endometrial Stromal Sarcoma (NCT05310318) | Lei Li | 2022-03-26 |
| Chromosomal Instability in Ovarian Cancer (NCT05310357) | Lei Li | 2022-03-26 |
| A Prospective Cohort Study Comparing Disparity in Surgical Procedure (Wide Local Excision Only vs Any Other Surgery Procedures) Among the Elderly Breast Cancer Patients (NCT04426136) | Peking Union Medical College Hospital | 2020-06-01 |
Track Survival Outcomes automatically
Every clearance here is in the API, with alerts when new ones post.